Neurocrine biosciences announces amendment to strategic collaboration with takeda to develop and commercialize osavampator (formerly nbi-1065845/tak-653)

-       neurocrine obtains exclusive worldwide development and commercialization rights excluding japan and converts to royalty-bearing license for osavampator -       takeda reacquires rights to osavampator in japan san diego , jan. 27, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced it has amended its agreement with takeda to develop and commercialize osavampator (nbi-1065845/tak-653). under the amended agreement, neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class ampa positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (mdd) in all territories worldwide except japan, where takeda will reacquire exclusive rights.
NBIX Ratings Summary
NBIX Quant Ranking